INS and MODY: The identification of biallelic variants among individuals diagnosed with diabetes in adolescence and individuals with non-insulin-treated diabetes has implications for treatment and genetic testing and indicates that inclusion of ZNF808 to genetic testing panels used for MODY should be considered.